TY - JOUR T1 - Surveillance by age-class and prefecture for emerging infectious febrile diseases with respiratory symptoms, including COVID-19 JF - medRxiv DO - 10.1101/2020.04.11.20061697 SP - 2020.04.11.20061697 AU - Tomoaki Ueno AU - Junko Kurita AU - Tamie Sugawara AU - Yoshiyuki Sugishita AU - Yasushi Ohkusa AU - Hirokazu Kawanohara AU - Miwako Kamei Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/15/2020.04.11.20061697.abstract N2 - Object The COVID-19 outbreak emerged in late 2019 in China, expanding rapidly thereafter. Even in Japan, epidemiological linkage of transmission was probably lost already by February 18, 2020. From that time, it has been necessary to detect clusters using syndromic surveillance.Method We identified common symptoms of COVID-19 as fever and respiratory symptoms. Therefore, we constructed a model to predict the number of patients with antipyretic analgesics (AP) and multi-ingredient cold medications (MIC) controlling well-known pediatric infectious diseases including influenza or RS virus infection. To do so, we used the National Official Sentinel Surveillance for Infectious Diseases (NOSSID), even though NOSSID data are weekly data with 10 day delays, on average. The probability of a cluster with unknown febrile disease with respiratory symptoms is a product of the probabilities of aberrations in AP and MIC, which is defined as one minus the probability of the number of patients prescribed a certain type of drug in PS compared to the number predicted using a model. This analysis was conducted prospectively in 2020 using data from October 1, 2010 through 2019 by prefecture and by age-class.Results The probability of unknown febrile disease with respiratory symptom cluster was estimated as less than 60% in 2020.Discussion The most severe limitation of the present study is that the proposed model cannot be validated. A large outbreak of an unknown febrile disease with respiratory symptoms must be experienced, at which time, practitioners will have to “wing it”. We expect that no actual cluster of unknown febrile disease with respiratory symptoms will occur, but if it should occur, we hope to detect it.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJapan Ministry of Health, Labour and Welfare. Press Releases. (in Japanese) https://www.mhlw.go.jp/stf/houdou/houdou_list_202003.html ER -